GOSS News and Press, Gossamer Bio Inc. From 11/09/23

- Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 - - $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 - Gossa...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Gossamer Bio Inc. (GOSS) is expected to report $-0.2 for Q3 2023

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medic...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the s...

2023-08-08 17:22:12 ET Gossamer Bio press release ( NASDAQ: GOSS ): Q2 GAAP EPS of -$0.45 beats by $0.04 . $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from a Private Placement Fin...

- Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 - - $374 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2023, Pro Forma for Gross Proceeds ...

2023-07-27 11:49:43 ET Gossamer Bio ( NASDAQ: GOSS ) fell ~4% Thursday noon after UBS downgraded the biopharmaceutical company, having said the next few years are more about execution. The ratings agency lowered the recommendation on the company to Neutral from Buy, and d...

- Call will be held on Tuesday, July 25 th beginning at 10 a.m. EDT - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced t...